Posted by Michael Wonder on 22 Nov 2017
Institute for Clinical and Economic Review report finds evidence limited on treatments for tardive dyskinesia; discounts of up to 90% needed to align cost of drugs with benefit to patient
21 November 2017 - Report will be subject to public deliberation during New England CEPAC meeting on 5 December 2017.
The Institute for Clinical and Economic Review (ICER) today released an evidence report assessing the comparative clinical effectiveness and value of three vesicular monoamine transporter-2 inhibitors for management of tardive dyskinesia (TD), a movement disorder often associated with long-term use of certain antipsychotic drugs. The report reviews evidence on valbenazine (Ingrezza, Neurocrine Biosciences) and deutetrabenazine (Austedo, Teva), both approved earlier this year for treatment of TD, as well as tetrabenazine (Xenazine, Lundbeck), which is approved for use in Huntington’s disease but has also been used to treat TD.
This Evidence Report will be the subject of an upcoming public meeting of the New England Comparative Effectiveness Public Advisory Council (New England CEPAC) in Newton, MA on 5 December 2017. The New England CEPAC is one of ICER’s three independent evidence appraisal committees comprising medical evidence experts, practicing clinicians, methodologists, and leaders in patient engagement and advocacy.
